Impact of Clinical Pharmacy Services Provided for Patients With Active Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
Enrolment of clinical pharmacy services in RA patients as a part of health care system has been investigated at many studies but not investigated in active RA patients before. This study aimed to detect drug therapy-related problems (DTRPs) in active rheumatoid arthritis (RA) patients and Investigate the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life (QoL). Methods:Prospective, randomized controlled study to be carried out at rheumatology outpatient clinic, Ain Shams University Hospitals on 50 patients with active RA for 6 months.determine if any drug therapy problems are present.Develop a plan of care that includes interventions to resolve drug therapy problems, achieve goals of therapy, and prevent drug therapy problems. questionnaires was used to measure functional status in RA patients using health assessment questionnaire (HAQ) and assess self-reported quality of life in patients with (RA) using rheumatoid arthritis quality of life questionnaire (RAQOL) and measure adherence using the 4-item Morisky Green Levine Medication Adherence Scale and Disease Activity Score-28 was used as an objective method to assess RA disease activity.

Official Title
-----------------
Impact of Clinical Pharmacy Services Provided for Patients With Active Rheumatoid Arthritis

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Other: pharmaceutical care services


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 18-60 years old fulfillment of the American College of Rheumatology /European league against rheumatism (2010 ACR/EULAR ) diagnostic criteria for RA. patients with active RA(defined by DAS28 score < 5.1) Exclusion Criteria: Patients with cognitive impairment. The presence of hepatic or renal disease. The presence of other rheumatic and connective tissue disorders.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| intervention<br>will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance. | Other: pharmaceutical care services<br>* detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life<br>|
| control<br>will received standard care by physician in attendance | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| disease activity score | disease activity score-28 (DAS-28) for measuring disease activity in rheumatoid arthritis patients | 6 months | 
| Quality of life questionnaire | Rheumatoid arthritis quality of life questionnaire (RAQOL) for measuring quality of life | 6 months | 
| Health assessment questionnaire | Health assessment questionnaire (HAQ) for measuring functional status in rheumatoid arthritis patients | 6 months |